2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Breast Cancer.

J Adv Pract Oncol · 2019 · PMC7520728 · PMID 33364068

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the global phase III NALA trial, treatment of metastatic HER2-positive breast cancer with neratinib plus capecitabine significantly improved progression-free survival, delayed the time to intervention for central nervous system disease, and showed a trend toward improved overall survival vs lapatinib plus capecitabine (Saura et al., 2019).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.